Tag Archives: Eli Lilly

Genetic Technologies Affirms Ariosa/Myriad With An Introduction By The Sequenom Petition for Cert.

On April 1st, Lilly filed an amicus brief in favor of Sequenom’s petition for cert. seeking to reverse Ariosa, that caused a lot of buzz in the IP community. (A copy is available at the end of this post.) To … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | 1 Comment

Lilly Files Amicus Brief in Myriad Remand – With Friends Like This…

Following its reversal of the Fed. Cir.’s decision in Mayo v. Prometheus (“Mayo”), the Supreme Court GVR’d in response to AMP’s (read: ACLU’s) appeal of Myriad’s claims to isolated DNA sequences and to a method of screening potential anti-cancer drugs … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

HUMAN GENOME SCIENCES v. ELI LILLY – Increased European Harmony?

By Paul Cole, European Patent Attorney, Lucas & Co – Warlingham, UK Judgement – Human Genome Sciences Inc (Appellant) v Eli Lilly and Company (Respondent) The above proceedings relate to European Patent (UK) 0,939,804 concerning a new  human  protein called Neutrokine-α. … Continue reading

Posted in EP and UK Practice | Tagged , , , , , , | 1 Comment

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

From Paul Cole The Lilly patent for olanzapine has been litigated in many jurisdictions including the US, Canada, the Czech Republic, Finland, Levitra order online Romania, Slovakia, Slovenia, Spain, China and Hungary. In US Court of Appeals for the Federal … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , | Leave a comment